Key Highlights

  • Phase 1 INSIGHT-003 trial reached a mature median overall survival of 30.9 months.
  • That result significantly exceeds the historical 22.0-month standard-of-care benchmark.
  • The survival benefit held even in patients with PD-L1 TPS below 50%.
  • The trial evaluated eftilagimod alfa (efti) combined with pembrolizumab and chemotherapy.

Full Story

Immutep Limited (NASDAQ: IMMP) reported positive mature overall survival data from its Phase 1 INSIGHT-003 trial, evaluating eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy in first-line non-small cell lung cancer (NSCLC). The trial reached a median overall survival of 30.9 months, a figure the company says significantly exceeds the historical 22.0-month benchmark typically associated with standard-of-care treatment in this setting.

Overall survival is widely considered the gold-standard endpoint in oncology clinical trials, since it directly measures whether a treatment helps patients live longer rather than relying on surrogate markers like tumor response rate or progression-free survival. A nearly nine-month improvement over historical benchmarks, if it holds up under further scrutiny and larger controlled trials, would represent a clinically meaningful advance in a disease setting where incremental survival gains have historically been hard-won.

Notably, Immutep highlighted that the survival benefit was consistent even in the subgroup of patients with PD-L1 tumor proportion score (TPS) below 50%. PD-L1 expression is a widely used biomarker for predicting how well patients will respond to checkpoint inhibitors like pembrolizumab, with lower-expressing tumors generally considered less responsive to immunotherapy alone. Efti's mechanism, which works by activating antigen-presenting cells through the LAG-3 pathway, is designed to complement checkpoint inhibition rather than depend solely on PD-L1 expression, and this data point suggests the combination may extend meaningful benefit to a broader population of NSCLC patients than checkpoint inhibitors alone typically reach.

The INSIGHT-003 results arrive alongside separate news from Immutep regarding a forensic investigation into a discontinued Phase 3 trial of the same drug, TACTI-004, which showed a markedly different and suppressed immune response profile. Investors will likely view the two updates together: the encouraging Phase 1 data reinforces confidence in efti's underlying biological mechanism and clinical potential, while the TACTI-004 investigation aims to determine whether that trial's disappointing outcome reflected an issue specific to manufacturing or drug exposure rather than a fundamental problem with the drug itself.

As a Phase 1 study, INSIGHT-003's dataset is necessarily smaller and less statistically robust than a pivotal Phase 3 trial would be, and mature survival data from early-stage studies should be interpreted with appropriate caution regarding sample size and trial design. Nonetheless, for a company navigating a difficult stretch following the TACTI-004 discontinuation, the INSIGHT-003 results provide an important data point supporting continued belief in efti's core science, and will likely factor into Immutep's future strategic and clinical development decisions for the drug in NSCLC and potentially other indications.